Rajkumar, S. Vincent

Daratumumab or active monitoring for high-risk smoldering multiple myeloma

Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., Lindsay, J., Baker, R. I., Suzuki, K., Kosugi, H., et al. (2025) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 121

The clinical significance of cereblon expression in multiple myeloma

Schuster, S. R., Kortuem, K. M., Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Ahmann, G., Kumar, S., Rajkumar, S. V., et al. (2014) · Leukemia Research

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 113

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Facon, T., Venner, C. P., Bahlis, N. J., Offner, F., White, D. J., Karlin, L., Benboubker, L., Rigaudeau, S., Rodon, P., Voog, E., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 104

Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement

Murray, D., Kumar, S. K., Kyle, R. A., Dispenzieri, A., Dasari, S., Larson, D. R., Vachon, C., Cerhan, J. R., & Rajkumar, S. V. (2019) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 102

Clinical course and prognosis of non‐secretory multiple myeloma

Chawla, S. S., Kumar, S. K., Dispenzieri, A., Greenberg, A. J., Larson, D. R., Kyle, R. A., Lacy, M. Q., Gertz, M. A., & Rajkumar, S. V. (2015) · European Journal of Haematology

Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 88

Uncovering the biology of multiple myeloma among African Americans: A comprehensive genomics approach

Baker, A., Braggio, E., Jacobus, S., Jung, S., Larson, D., Therneau, T., Dispenzieri, A., Van Wier, S. A., Ahmann, G., Levy, J., et al. (2013) · Blood

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 66

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

Madan, S., Lacy, M. Q., Dispenzieri, A., Gertz, M. A., Buadi, F., Hayman, S. R., Detweiler-Short, K., Dingli, D., Zeldenrust, S., Lust, J., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 60

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma

Vu, T., Gonsalves, W., Kumar, S., Dispenzieri, A., Lacy, M. Q., Buadi, F., Gertz, M. A., & Rajkumar, S. V. (2015) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 51

Clarification of the definition of complete response in multiple myeloma

Durie, B. G. M., Miguel, J. F. S., Blade, J., Rajkumar, S. V., & on behalf of the International Myeloma Working Group (2015) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 42

Progress in Myeloma — A Monoclonal Breakthrough

Rajkumar, S. V., & Kyle, R. A. (2016) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 40

Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Durie, B. G., Hoering, A., Sexton, R., Abidi, M. H., Epstein, J., Rajkumar, S. V., Dispenzieri, A., Kahanic, S. P., Thakuri, M. C., Reu, F. J., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 34

Monoclonal gammopathy of undetermined significance

Rajkumar, S. V., & Kumar, S. (2025) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 31

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

Lonial, S., Jacobus, S. J., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A., Buadi, F., O'Brien, T. E., Matous, J., et al. (2019) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 28

Thalidomide in the treatment of multiple myeloma

Rajkumar, S. V. (2001) · Expert Review of Anticancer Therapy

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 25

Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination

Terpos, E., Rajkumar, S. V., & Leung, N. (2022) · JAMA Oncology

SARS-CoV-2 and COVID-19 ResearchMultiple Myeloma Research and Treatments

Cited by 22

Genomics define malignant transformation in myeloma precursor conditions

Maura, F., Bergsagel, P. L., Ziccheddu, B., Kumar, S., Maclachlan, K., Derkach, A., Garces, J.-J., Firestone, R., Braggio, E., Asmann, Y., et al. (2026) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 18

Temporal genomic dynamics shape clinical trajectory in multiple myeloma

Maura, F., Kaddoura, M., Poos, A. M., Baughn, L. B., Ziccheddu, B., Bärtsch, M.-A., Cirrincione, A., Maclachlan, K., Chojnacka, M., Diamond, B., et al. (2025) · Nature Genetics

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 14